Innate Pharma ADR Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Free Cash Flow -$62.1MTTM through 31 Dec 2025
Margins
| Current | |
|---|---|
| Operating Margin | -1,916.9% |
| Net Margin | -546.1% |
Returns
N/A (negative equity)ROE
-78.4%ROA
Balance Sheet Health
Debt / EquityN/A (negative equity)
Current Ratio1.27x
Net Debt-$28.4Mnet cash position
Cash & Equivalents$28.1M
Quality Metrics
Piotroski F-Score0 / 9
FCF Margin-587.4%
Multi-Year Trend
RevenueFY2025: $9M
Diluted EPSFY2025: $-0.55
Dividend
No dividend
Capital Allocation
Capex Intensity1.3%
Financials converted at 0.8513 from EUR.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.